Epoetin alfa is a human erythropoietin produced in cell culture using recombinant DNA technology.[6] Authorised by the European Medicines Agency on 28 August 2007, it stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy.
Epoetin is manufactured and marketed by Amgen under the brand name Epogen. Johnson & Johnson subsidiary Janssen Biotech (formerly Ortho Biotech Products, LP), sells the same drug under the name Procrit, pursuant to a product license agreement. The average cost per patient in the U.S. was $8,447 in 2009.[7] Darbepoetin alfa (rINN) /dɑːrbəˈpɔɪtɪn/ is a glycosylation analog of erythropoietin containing two additional N-linked carbohydrate chains,[8] also manufactured and marketed by Amgen, with a brand name of Aranesp. The Food and Drug Administration (FDA) warnings and safety precautions for Procrit, Epogen and Aranesp are identical.
For several years, epoetin alfa has accounted for the single greatest drug expenditure paid by the U.S. Medicare system; in 2010, the program paid $2 billion for the drug.[9][10] Raising hemoglobin levels has been found in some studies to be associated with higher risks of thrombotic events, strokes and death.[11]
It is on the World Health Organization's List of Essential Medicines.[12]
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^"Epogen- epoetin alfa solution". DailyMed. 25 July 2018.
^"Retacrit- epoetin alfa-epbx injection, solution". DailyMed. 29 January 2020.
^Cite error: The named reference Abseamed EPAR was invoked but never defined (see the help page).
^"Abseamed". Union Register of medicinal products. Retrieved 14 January 2021.
^Walsh G, Spada S (2005). "Epogen/Procrit". Directory of approved biopharmaceutical products. Boca Raton: CRC Press. pp. 39–41. ISBN 978-0-415-26368-9.
^Engelberg AB, Kesselheim AS, Avorn J (November 2009). "Balancing innovation, access, and profits--market exclusivity for biologics". The New England Journal of Medicine. 361 (20): 1917–9. doi:10.1056/NEJMp0908496. PMID 19828525.
^Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, et al. (April 2003). "Enhancement of therapeutic protein in vivo activities through glycoengineering". Nature Biotechnology. 21 (4): 414–21. doi:10.1038/nbt799. PMID 12612588. S2CID 7214868.
^"Testimony Before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives.] Medicare. Information on Highest-Expenditure Part B Drugs." (PDF), United States Government Accountability Office (GAO), 28 June 2013, retrieved 29 June 2015
^Mitka M (14 August 2013), "Capitol Health Call: High-Cost Drugs Account for Most of Medicare Part B Spending", JAMA, 310 (6): 572, doi:10.1001/jama.2013.192555
^Anemia drugs made billions, but at what cost? By Peter Whoriskey, The Washington Post, 19 July 2012
^World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Epoetinalfa is a human erythropoietin produced in cell culture using recombinant DNA technology. Authorised by the European Medicines Agency on 28 August...
addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels)...
called erythropoiesis-stimulating agents (ESA): two examples are epoetinalfa and epoetin beta. ESAs are used in the treatment of anemia in chronic kidney...
has been available for use in medical treatment.[citation needed] EpoetinalfaEpoetin theta Centers for Medicare and Medicaid Services: Erythrocyte Stimulating...
Interferon alfa (INN) or HuIFN-alpha-Le, trade name Multiferon, is a pharmaceutical drug composed of natural interferon alpha (IFN-α), obtained from the...
white blood cell counts and neutrophil counts. Blood transfusions and epoetinalfa help with anemia. Computational analysis on a panel of osteosarcoma cell...
blood cell production. Lin's team created what would become Epogen (epoetinalfa). 1984: In June, Amgen and Kirin formed a joint venture giving Kirin...
EpoetinAlfa Dosing as Maintenance Treatment for the Anemia of Chronic Kidney Disease, Provenzano, R., Bhaduri, S., Singh, A., Extended EpoetinAlfa Dosing...
every 3 to 4 weeks demonstrated efficacy similar to that of epoetinalfa and darbepoetin alfa in maintaining hemoglobin concentrations within the target...
interferon alfa. The recombinant type is interferon alfacon-1. The pegylated types are pegylated interferon alfa-2a and pegylated interferon alfa-2b. Recombinant...
as:[citation needed] Epoetinalfa, a synthetic erythropoietin that stimulates stem cells to produce red blood cells. Darbepoetin alfa stimulates red blood...
the anemia of chronic kidney disease, recombinant erythropoietin or epoetinalfa is recommended to stimulate RBC production, and if iron deficiency and...
to treat neutropenia and fungal infections in cancer patients Interferon alfa, used to treat hepatitis C and multiple sclerosis Interferon beta, used to...
Initiative, 9 November 2012 Sandoz starts phase III US trial for biosimilar epoetinalfa Archived 20 October 2013 at the Wayback Machine "20-F". www.sec.gov....
Global Information
(what is this?) (verify)